Press release; Senzime receives CE mark approval for the OnZurf Probe

Uppsala, December 18, 2017. Senzime AB (publ) announces that the company has received CE mark approval for the OnZurf Probe, which means that the product now is approved for sale on the European market.

Press release; Senzime receives CE mark approval for the TetraGraph

Uppsala, December 12, 2017.  Senzime AB (publ) announced today that it has received CE mark approval to enable the commercialization of the TetraGraph Neuromuscular Monitoring System. 

Senzime’s Interim report January – September 2017

Uppsala, November 28, 2017. Senzime AB’s (publ) Interim report for January – September 2017 is now available on the company’s webbsite www.senzime.com.

Comparative Investigation of TetraGraph and TOF-Watch SX

Press release Uppsala, 23 October 2017. Dr Réka Nemes at the University of Debrecen, Department of Anesthesiology and Intensive Care, Debrecen, Hungary, reports results from the Comparative Investigation of TetraGraph and TOF-Watch SX. 

Senzime submits 510 (k) application to the FDA

Uppsala, September 25, 2017. Senzime AB (publ) announced today that the company has submitted a 510 (k) application to the US Food and Drug Administration (FDA) for approval of the TetraGraph in the United States. 

Senzime signs distribution agreement for the Swiss market

Uppsala, September 18, 2017. Senzime AB (publ) today announced an exclusive distribution agreement with Leuag AG regarding the Swiss market.

RESOLUTIONS AT SENZIME AB’S (PUBL) EXTRAORDINARY GENERAL MEETING

Senzime AB (publ) (the “Company”) held its Extraordinary General Meeting on September 15, 2017 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.

Notice of Extraordinary General Meeting of Senzime for the introduction of an employee stock option program

Uppsala, August 31, 2017. Senzime AB (publ) calls for an Extraordinary General Meeting for the introduction of an employee stock option program. The Board proposes that the General Meeting approve resolutions to issue no more than 1,300,000 warrants and to introduce an employee stock option plan. 

Senzime’s Interim report January – June 2017

Uppsala, August 31, 2017. Senzime AB’s (publ) Interim report for January – June 2017 is now available on the company’s webbsite www.senzime.com.

Senzime obtains US patent

Uppsala, August 9, 2017. Senzime AB (publ) is awarded a U.S. patent for its TetraSens disposable electrodes. With its unique design, the TetraSens enables fast application and effective function. The electrodes are used in conjunction with Senzime's neuromuscular monitoring system, the TetraGraph, which contributes to effective, continuous monitoring of patients undergoing anesthesia and surgical muscle relaxation. The TetraGraph, via the interfaced TetraSens electrodes, makes it possible to easily and objectively determine the optimal dose of neuromuscular blocking drugs administered during the procedure, and to establish the appropriate time when it is safe to wake the patient after surgery and allow spontaneous breathing without the help of a ventilator.